Hepatic gluconeogenesis and insulin signaling pathway

The hepatic gluconeogenesis and insulin signaling pathways are critical systems for maintaining blood glucose levels within a narrow physiological range. Hepatic gluconeogenesis involves the synthesis of glucose from non-carbohydrate sources like lactate and amino acids, a process regulated by enzymes such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) (StatPearls: Gluconeogenesis, 2023). Insulin sensitivity pathways, primarily the PI3K/Akt signaling cascade, mediate the body's response to insulin, which normally suppresses hepatic glucose production by inhibiting the transcription factor FOXO1 (NIH: Insulin Signaling Pathway, 2022). Dysregulation of these pathways is a hallmark of type 2 diabetes and metabolic syndrome, where insulin resistance leads to uncontrolled hepatic glucose output and fasting hyperglycemia (Nature Reviews Endocrinology, 2021). Therapeutic strategies include the use of metformin to activate AMPK and inhibit gluconeogenesis, or thiazolidinediones to enhance insulin sensitivity via PPAR-gamma activation (PubChem: Metformin; PubMed: PMC3482487). Understanding these integrated pathways is essential for developing treatments that address the underlying metabolic defects in insulin-resistant states.

Other names

Hepatic glucose productionInsulin sensitivity pathwayGluconeogenic pathwayInsulin signaling cascadeHGP pathway

Pharmacological agents modulate these pathways through several mechanisms: metformin activates AMPK to decrease the expression of gluconeogenic genes; thiazolidinediones act as PPAR-gamma agonists to improve peripheral and hepatic insulin sensitivity; and GLP-1 receptor agonists enhance glucose-dependent insulin secretion while suppressing glucagon-mediated gluconeogenesis (StatPearls: Metformin, 2023; PubMed: PMC2596737).